Chartwell Investment Partners, LLC Relmada Therapeutics, Inc. Transaction History
Chartwell Investment Partners, LLC
- $2.91 Billion
- Q3 2024
Shares
4 transactions
Others Institutions Holding RLMD
# of Institutions
49Shares Held
6.3MCall Options Held
0Put Options Held
0-
Acadian Asset Management LLC Boston, MA1.23MShares$503,4500.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.21MShares$495,3100.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$235,0580.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA495KShares$203,0090.03% of portfolio
-
Geode Capital Management, LLC Boston, MA302KShares$123,7720.0% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $11.7M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...